Click on the protein name for more information about the protein.
The Score column is the predicted score of interaction between the two proteins
Click on the Evidence link to view a breakdown of the information about the predicted interaction.
Key | |
---|---|
Module Score | Databases |
![]() | Where interaction is observed in another database a link is provided: |
Protein 1 (?) | Protein 2 (?) | Name of Protein 2 | Module Scores (?) | Scores (?) | Evidence (?) | Database (?) | |||
---|---|---|---|---|---|---|---|---|---|
![]() | ![]() | ![]() | ![]() | ||||||
MAPK10 | FOS | FOS, G0S7: Proto-oncogene protein c-fos | 24.90 | Evidence | |||||
MAPK10 | FOSL2 | FOSL2, FRA2: Fos-related antigen 2 | 24.90 | Evidence | |||||
MAPK10 | MAP2K2 | MAP2K2, MEK2, MKK2, PRKMK2: Dual specificity mitogen-activated protein kinase ki | 19.10 | Evidence | |||||
MAPK10 | SYK | SYK: Tyrosine-protein kinase SYK | 15.00 | Evidence | |||||
MAPK10 | BLNK | BLNK, BASH, SLP65: B-cell linker protein | 15.00 | Evidence | |||||
MAPK10 | LYN | LYN: Tyrosine-protein kinase Lyn | 15.00 | Evidence | |||||
MAPK10 | RASA3 | RASA3: Ras GTPase-activating protein 3 | 15.00 | Evidence | |||||
MAPK10 | MAPK3 | MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 | 9.96 | Evidence | |||||
MAPK10 | MAP2K1 | MAP2K1, MEK1, PRKMK1: Dual specificity mitogen-activated protein kinase kinase 1 | 9.96 | Evidence | |||||
MAPK10 | MAPK1 | MAPK1, ERK2, PRKM1, PRKM2: Mitogen-activated protein kinase 1 | 9.96 | Evidence | |||||
MAPK10 | RPL8 | RPL8: 60S ribosomal protein L8 | 3.34 | Evidence | |||||
MAPK10 | FOSL1 | FOSL1, FRA1: Fos-related antigen 1 | 2.91 | Evidence | |||||
MAPK10 | CREBBP | CREBBP, CBP: CREB-binding protein | 1.71 | Evidence | |||||
MAPK10 | DUSP16 | DUSP16, KIAA1700, MKP7: Dual specificity protein phosphatase 16 | 1.13 | Evidence |
![]() |
||||
MAPK10 | PTEN | PTEN, MMAC1, TEP1: Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and du | 1.13 | Evidence | |||||
MAPK10 | DUSP6 | DUSP6, MKP3, PYST1: Dual specificity protein phosphatase 6 | 1.13 | Evidence |